Latest From Biotech Now

Voting is now open for the Future Makers of Biotech!

CeqDEHrWwAAZMOZ

Imagine for a moment, a world free of disease, hunger, or threats to our environment. A future in which anything is possible, and our only limitation is the extent of our creativity and our passion to change the world. For the thousands of innovative treatments and scientific advancements we have today, there were believers who overcame enormous obstacles to make the world a little better for all of us. We call these individuals “future makers” Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Star-Telegram: Prescription Drug Price Controls Pose Lethal Problems

medicine

In case you missed it, the Fort Worth Star-Telegram ran an op-ed by Thomas P. Stossel, American Cancer Society Professor of Medicine at Harvard and a visiting scholar of the American Enterprise Institute, discussing the Democratic Presidential Candidates plans for drug pricing controls and the adverse impact they will have on patients. Read more in the Star-Telegram.

Health  |  Leave a comment  |  Email This Post
Tags: , ,

NIH Office of Science Policy Unveils New Resources

shutterstock_27160801

The NIH Office of Science Policy (OSP) works on a wide range of issues including biosafety, biosecurity, genetic testing, genomic data sharing, human subjects protections, the organization and management of the NIH, and the outputs and value of NIH-funded research. This is accomplished through a wide range of analyses and reports, commentary on emerging policy proposals, and the development of policy proposals for consideration by NIH, the Federal government, and the public. To better align Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post

Judd Gregg: Biodefense Funding Is Crucial to National Security

ebola

Writing in the Morning Consult, former Senator Judd Gregg explains critical role of federal programs in preparing our nation for viral outbreaks and other biohazards that threaten to cause devastating harm to our national security. Because there is no commercial market for medical countermeasures to respond to attacks from chemical, biological, nuclear and radiological threats, in 2004 Congress passed the Project BioShield Act, which created the Project BioShield Special Reserve Fund (SRF) to incentivize research Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , ,

JAMA Study Finds Vast Majority of Requests for Clinical Trial Data Granted

cells115x76

In 2014, BIO members reaffirmed and broadened their commitment to responsibly share data from clinical trials with other researchers, including academic and government researchers, in an effort to support additional efforts to improve public health. A JAMA study released yesterday shows that biopharmaceutical companies are keeping that commitment, approving the vast majority of requests for patient-level data from clinical trials. The study looked at three platforms containing clinical trial data from 14 drug companies. Of Read More >

Health  |  Leave a comment  |  Email This Post
Tags: ,